Meiragtx Holdings Plc shares rose 3.5% in pre-market trading.

Previously, the company announced it had secured a strategic investment of up to $400 million from Oberland Capital. This significant capital infusion is expected to greatly strengthen Meiragtx’s R&D capabilities and operational funding reserves. The market responded positively, with the stock price’s rise reflecting an increased investor confidence in the company’s future development. Strategic investments typically mean that investors provide not only funds, but may also bring industry resources and strategic synergies. This injection from Oberland Capital is likely to provide strong momentum for Meiragtx’s deeper exploration in the field of gene therapy.